Markets

Insider Trading

Hedge Funds

Retirement

Opinion

Precipio, Inc. (NASDAQ:PRPO) Q1 2023 Earnings Call Transcript

Precipio, Inc. (NASDAQ:PRPO) Q1 2023 Earnings Call Transcript May 18, 2023

Operator: Welcome to the Precipio Q1 2023 Shareholder Update Conference Call. All participants will be in listen-only mode. Please note that the conference is being recorded. Statements made during this call contain forward-looking statements about our business. You should not place undue reliance on forward-looking statements as these statements are based upon our current expectations, forecasts and assumptions, and are subject to significant risks and uncertainties. These statements may be identified by words such as may, will, should, could, expect, intend, plan, anticipate, believe, estimate, predict, potential, forecast, continue or the negative of these terms or other words or terms of similar meaning. Risks and uncertainties that could cause our actual results to differ materially from these set forth in any forward-looking statements include, but are not limited to, the matters listed under Risk Factors in our annual report on Form 10-K for the year ended December 31, 2022, which is on file with the Securities and Exchange Commission as well as other risks detailed in our subsequent filings with the Securities and Exchange Commission.

These reports are available at www.sec.gov. Statements and information, including forward-looking statements, speak only to the date they are provided, unless an earlier date is indicated, and we do not undertake any obligation to publicly update any statements or information, including forward-looking statements, whether as a result of new information, future events or otherwise, except as required by law. Now let me hand the call over to Ilan Danieli, Precipio’s CEO. Please go ahead.

Ilan Danieli: Thank you, and good afternoon. And thanks for joining our Q1 2023 shareholder update call. Today, I’d like to spend some time discussing the progress we’re making in our revenue growth and our journey towards breakeven. I’ll start by sharing updates on the Pathology Services Division and then follow up with a more detailed discussion on the Product Division, and in particular, I’d like to provide some more color around the catalysts we provided in today’s earlier press release. Let’s start with the Pathology Services Division. I’m pleased to report that this was yet another record quarter with revenues of over $2 million. Furthermore, with the addition of the customer announced earlier this month, as well as other new business, we will surpass the $11 million run rate and are advancing towards the breakeven mark for this division.

Our case volume, average revenue per case, collections and other key metrics continue to trend upward as we drive this division towards anticipated profitability. Additionally, we’re working on several operational cost-cutting measures within the division intended to reduce expenses and increase gross margins, which will ultimately bring the breakeven number closer and help us reach it sooner. Company management is focused on this goal. Now moving to the Product Division, as we previously announced in a formal filing, we had a record quarter of product sales, exceeding $750,000 per quarter, which is equivalent to a $3 million run rate. We have since continued to add business and are moving closer to the $4 million run rate. I’d like to take a few moments to share how we got there by reviewing the three catalysts we measure as indicators of growth and why we believe this trend will continue.

As we recapped, in late 2022, we signed agreements with major healthcare distributors such as ThermoFisher and others, gaining access to over 200 world class sales reps. Needless to say, engaging such a large group is a massive undertaking, and it happens gradually. Not all sales reps are born equally. They have different interests, different levels of opportunities to new technologies and different levels of comfort with taking a new product to their customers. Just like with many new products, the early adopters are quick to jump to the opportunity, while there are others who will sit on the sideline for a while and watch how we progress to make sure that we, as a new vendor, deliver on our promise. As we said in today’s PR, the first catalyst we look at is rep engagement, which has increased from 16% to 37% since the start of the year.

This is a solid accomplishment in such a short period of time, and we will continue to drive to grow these numbers. One of the questions that came up was how do we measure rep engagement. We’ve defined this as when a rep brings us a qualified vetted customer. This means that the rep has taken the time to learn about the product, understand our target customer, studied the qualifying criteria for our customer, and then conduct the research intended to indeed ensure that the customer is a qualified, quality lead, which represents a real potential for business. This leads me to the next catalyst we look at, qualified leads in our pipeline. As a new customer serves as another building block to our revenue, and once on-boarded, this customer will generate recurring revenue to the company.

As we stated today, our qualified leads grew from 30 to 78, representing a 150% increase since the end of 2022. Sales is very much a shot on goal process. But since our filter is to ensure the leads coming into the funnel are vetted to ensure there’s a fit, we’ve created a high quality sales funnel with qualified, interested customers who are interested in our products. The last catalyst we shared today is the revenue pipeline, which increased from $3.3 million to $6.2 million over the same period since the end of 2022. While these are, by no means, huge numbers, there are three factors I’d like for you to keep in mind. First, the total available market for HemeScreen is estimated over $400 million annually in the U.S. alone. So we have lots of potential market share to grow into.

Second, our breakeven point for the company is $8 million of HemeScreen sales. And so the current pipeline, when added to our existing business, represents a clear path to reach that goal. And lastly, the pipeline number shared is net of conversions to new customers. What this means is that as we continue to sign deals and convert pipeline into account — or pipeline accounts into actual customers, as we have this quarter, this takes dollars out of the pipeline because they are now actual customers and no longer pipeline. The increase in pipeline means that we not only fill the gap created by the conversion of pipeline leads into actual accounts, but this also added more potential revenue to the pipeline. This happens because, over time, more reps become engaged as they see the value of our product, and they are bringing us more qualified accounts to offer the products to.

We expect this trend will continue as more and more sales reps see the success of their customers’ adoption of HemeScreen into their lab. I’d like to end with an anecdotal story that recently took place. One of our HemeScreen customers recently added our AML panel. As a reminder, AML or acute myeloid leukemia, is one of the most deadliest cancers. It’s essentially the code red of hematologic malignancies. When the patient comes in presenting with acute leukemia or suspected acute leukemia, he or she is typically rushed to the hospital to begin immediate treatment, and this treatment is oftentimes very aggressive. With the advent of targeted therapies, molecular or genetic tests are a key part of the diagnosis and development of treatment plan for the patients.

However, most tests take at least 7 to 10 days to receive results. If the doctor waits for those results to begin treatment, there’s a decent chance that patients will not even make it due to the aggressive nature of the disease. Therefore, the doctor oftentimes has no choice but to begin treatment immediately without waiting for these important test results. Precipio AML panel is designed to provide same-day results to the patient. And in this case, it did. The customer rushed the sample to the lab, and the lab provided immediate results to the clinician who is able to make a far more informed decision based on the molecular results received from the HemeScreen AML panel. Incidentally, the testing for this patient found three mutations, which is quite a unique outcome that can completely change the course of treatment.

Getting these results within a day versus a week was a life-impacting game changer. Precipio’s team was supporting the customer during their onboarding and launch of the test, and we were proud to be part of the process that makes such an impact on the patient’s lives. Lastly, I’d like to address the share price and several people’s concerns of meeting the NASDAQ $1 requirement. As you know, we received an extension from NASDAQ, and we now have until October to meet the $1 requirement. As our company continues to make progress and advance towards financial independence, increasing revenue and reducing its cash burn, we believe this will be reflected in the share price as a multiple of these factors. Since the share price is the one thing we can’t control, management and our entire company is laser-focused on two goals, growing revenue and advancing towards breakeven.

And we are accomplishing both. And looking at other comparable companies in our sector, we’ll be one of the few companies to achieve breakeven at such a low revenue number. Furthermore, the combination of large addressable markets, high margins and an engine that continues to develop new proprietary products at almost no cost, presents, in our opinion, a market cap that translates into a share price far above $1. I’d like to thank you for attending the call today, and I look forward to connecting with you again after our next quarter results are out. Thank you, and have a nice evening.

Operator: The conference has now concluded. Thank you for attending today’s presentation. You may now disconnect.

Follow Precipio Inc. (NASDAQ:PRPO)

AI, Tariffs, Nuclear Power: One Undervalued Stock Connects ALL the Dots (Before It Explodes!)

Artificial intelligence is the greatest investment opportunity of our lifetime. The time to invest in groundbreaking AI is now, and this stock is a steal!

AI is eating the world—and the machines behind it are ravenous.

Each ChatGPT query, each model update, each robotic breakthrough consumes massive amounts of energy. In fact, AI is already pushing global power grids to the brink.

Wall Street is pouring hundreds of billions into artificial intelligence—training smarter chatbots, automating industries, and building the digital future. But there’s one urgent question few are asking:

Where will all of that energy come from?

AI is the most electricity-hungry technology ever invented. Each data center powering large language models like ChatGPT consumes as much energy as a small city. And it’s about to get worse.

Even Sam Altman, the founder of OpenAI, issued a stark warning:

“The future of AI depends on an energy breakthrough.”

Elon Musk was even more blunt:

“AI will run out of electricity by next year.”

As the world chases faster, smarter machines, a hidden crisis is emerging behind the scenes. Power grids are strained. Electricity prices are rising. Utilities are scrambling to expand capacity.

And that’s where the real opportunity lies…

One little-known company—almost entirely overlooked by most AI investors—could be the ultimate backdoor play. It’s not a chipmaker. It’s not a cloud platform. But it might be the most important AI stock in the US owns critical energy infrastructure assets positioned to feed the coming AI energy spike.

As demand from AI data centers explodes, this company is gearing up to profit from the most valuable commodity in the digital age: electricity.

The “Toll Booth” Operator of the AI Energy Boom

  • It owns critical nuclear energy infrastructure assets, positioning it at the heart of America’s next-generation power strategy.
  • It’s one of the only global companies capable of executing large-scale, complex EPC (engineering, procurement, and construction) projects across oil, gas, renewable fuels, and industrial infrastructure.
  • It plays a pivotal role in U.S. LNG exportation—a sector about to explode under President Trump’s renewed “America First” energy doctrine.

Trump has made it clear: Europe and U.S. allies must buy American LNG.

And our company sits in the toll booth—collecting fees on every drop exported.

But that’s not all…

As Trump’s proposed tariffs push American manufacturers to bring their operations back home, this company will be first in line to rebuild, retrofit, and reengineer those facilities.

AI. Energy. Tariffs. Onshoring. This One Company Ties It All Together.

While the world is distracted by flashy AI tickers, a few smart investors are quietly scooping up shares of the one company powering it all from behind the scenes.

AI needs energy. Energy needs infrastructure.

And infrastructure needs a builder with experience, scale, and execution.

This company has its finger in every pie—and Wall Street is just starting to notice.

Wall Street is noticing this company also because it is quietly riding all of these tailwinds—without the sky-high valuation.

While most energy and utility firms are buried under mountains of debt and coughing up hefty interest payments just to appease bondholders…

This company is completely debt-free.

In fact, it’s sitting on a war chest of cash—equal to nearly one-third of its entire market cap.

It also owns a huge equity stake in another red-hot AI play, giving investors indirect exposure to multiple AI growth engines without paying a premium.

And here’s what the smart money has started whispering…

The Hedge Fund Secret That’s Starting to Leak Out

This stock is so off-the-radar, so absurdly undervalued, that some of the most secretive hedge fund managers in the world have begun pitching it at closed-door investment summits.

They’re sharing it quietly, away from the cameras, to rooms full of ultra-wealthy clients.

Why? Because excluding cash and investments, this company is trading at less than 7 times earnings.

And that’s for a business tied to:

  • The AI infrastructure supercycle
  • The onshoring boom driven by Trump-era tariffs
  • A surge in U.S. LNG exports
  • And a unique footprint in nuclear energy—the future of clean, reliable power

You simply won’t find another AI and energy stock this cheap… with this much upside.

This isn’t a hype stock. It’s not riding on hope.

It’s delivering real cash flows, owns critical infrastructure, and holds stakes in other major growth stories.

This is your chance to get in before the rockets take off!

Disruption is the New Name of the Game: Let’s face it, complacency breeds stagnation.

AI is the ultimate disruptor, and it’s shaking the foundations of traditional industries.

The companies that embrace AI will thrive, while the dinosaurs clinging to outdated methods will be left in the dust.

As an investor, you want to be on the side of the winners, and AI is the winning ticket.

The Talent Pool is Overflowing: The world’s brightest minds are flocking to AI.

From computer scientists to mathematicians, the next generation of innovators is pouring its energy into this field.

This influx of talent guarantees a constant stream of groundbreaking ideas and rapid advancements.

By investing in AI, you’re essentially backing the future.

The future is powered by artificial intelligence, and the time to invest is NOW.

Don’t be a spectator in this technological revolution.

Dive into the AI gold rush and watch your portfolio soar alongside the brightest minds of our generation.

This isn’t just about making money – it’s about being part of the future.

So, buckle up and get ready for the ride of your investment life!

Act Now and Unlock a Potential 100+% Return within 12 to 24 months.

We’re now offering month-to-month subscriptions with no commitments.

For a ridiculously low price of just $9.99 per month, you can unlock our in-depth investment research and exclusive insights – that’s less than a single fast food meal!

Space is Limited! Only 1000 spots are available for this exclusive offer. Don’t let this chance slip away – subscribe to our Premium Readership Newsletter today and unlock the potential for a life-changing investment.

Here’s what to do next:

1. Head over to our website and subscribe to our Premium Readership Newsletter for just $9.99.

2. Enjoy a month of ad-free browsing, exclusive access to our in-depth report on the Trump tariff and nuclear energy company as well as the revolutionary AI-robotics company, and the upcoming issues of our Premium Readership Newsletter.

3. Sit back, relax, and know that you’re backed by our ironclad 30-day money-back guarantee.

Don’t miss out on this incredible opportunity! Subscribe now and take control of your AI investment future!


No worries about auto-renewals! Our 30-Day Money-Back Guarantee applies whether you’re joining us for the first time or renewing your subscription a month later!

A New Dawn is Coming to U.S. Stocks

I work for one of the largest independent financial publishers in the world – representing over 1 million people in 148 countries.

We’re independently funding today’s broadcast to address something on the mind of every investor in America right now…

Should I put my money in Artificial Intelligence?

Here to answer that for us… and give away his No. 1 free AI recommendation… is 50-year Wall Street titan, Marc Chaikin.

Marc’s been a trader, stockbroker, and analyst. He was the head of the options department at a major brokerage firm and is a sought-after expert for CNBC, Fox Business, Barron’s, and Yahoo! Finance…

But what Marc’s most known for is his award-winning stock-rating system. Which determines whether a stock could shoot sky-high in the next three to six months… or come crashing down.

That’s why Marc’s work appears in every Bloomberg and Reuters terminal on the planet…

And is still used by hundreds of banks, hedge funds, and brokerages to track the billions of dollars flowing in and out of stocks each day.

He’s used this system to survive nine bear markets… create three new indices for the Nasdaq… and even predict the brutal bear market of 2022, 90 days in advance.

Click to continue reading…